Literature DB >> 22752833

Peripheral oedema as a side-effect of fluticasone.

Alice Myers1, Charles Godden.   

Abstract

A 14-year-old girl had experienced gross peripheral oedema for nearly 2 years. She was under review by several paediatric specialists for a variety of problems. Her local paediatric team were unable to find the cause of her oedema, despite extensive investigations. Eventually, her mother discovered the cause was inhaled fluticasone, prescribed at normal dosage for asthma. As far as the authors are aware, this is the first reported case of peripheral oedema associated with the use of fluticasone. Peripheral oedema is a rare side-effect of fluticasone in the form of either seretide or flixotide. Physicians should be aware of this possibility in cases of resistant peripheral oedema with no other identified cause.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22752833      PMCID: PMC3034203          DOI: 10.1136/bcr.09.2009.2264

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease.

Authors:  S D Singh; C Whale; N Houghton; P Daley-Yates; S M Kirby; A A Woodcock
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

2.  Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases.

Authors:  M Elliott; R Bayly; T Cole; I K Temple; E R Maher
Journal:  Clin Genet       Date:  1994-08       Impact factor: 4.438

3.  A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.

Authors:  Michael J Perrio; Lynda V Wilton; Saad A W Shakir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-09       Impact factor: 2.890

  3 in total
  1 in total

1.  Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease.

Authors:  Ye Yang; Lei Huang; Chongchong Tian; Bingjun Qian
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.